At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
lenalidomide (Revlimid®) +2 moredrug
Likely dose
lenalidomide (Revlimid®) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating lenalidomide (Revlimid®), Cyclophosphamide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionDec 2012
Study CompletionAug 2014
TodayJul 2026
First PostedOct 8, 2007
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2012
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 18.7 years ago
Interventions
lenalidomide (Revlimid®)drug
25 mg p.o. daily on days 1-21 of each 28 day cycle
Cyclophosphamidedrug
50 mg p.o. BID daily on days 1-21 of each 28 day cycle
Prednisonedrug
50 mg p.o. Q.O.D.